6 years ago

Ikarovec Secures £2.5 Million Seed Funding for Ophthalmic Gene Therapies

  • Ikarovec, a Cambridge, UK-based ophthalmic gene therapy company, has raised £2.5 million in seed funding from UKI2S, LifeArc and Parkwalk

  • The company plans to use the funds to develop its three earlier stage novel gene therapy products for major ophthalmic indications, build its intellectual property portfolio and establish its own laboratories

  • Ikarovec's lead program is a multicistronic gene therapy for diabetic macular edema (DME), to IND-enabling studies

  • Other programs are targeting wet age-related macular degeneration (AMD), dry AMD and intra-ocular hypertension.

      • ProblemHealthcare

      "Ikarovec is developing novel gene therapies to treat major ophthalmic indications, including diabetic macular edema (DME), wet age-related macular degeneration (AMD), dry AMD, and intra-ocular hypertension."

      Solution

      "Ikarovec's lead program is a multicistronic gene therapy for diabetic macular edema (DME), which is advancing towards IND-enabling studies. Other programs target other ophthalmic indications."

      Covered on